Biomedical Applications Of Georgia, Inc is a medicare approved dialysis facility center in Summerville, Georgia and it has 16 dialysis stations. It is located in Chattooga county at 12541 Highway 27, Summerville, GA, 30747.
You can reach out to the office of Biomedical Applications Of Georgia, Inc at (706) 857-4050. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Biomedical Applications Of Georgia, Inc has the following ownership type - Profit. It was first certified by medicare in November, 2017. The medicare id for this facility is 112795 and it accepts patients under medicare ESRD program.
Dialysis Center Profile
| Name | Biomedical Applications Of Georgia, Inc |
|---|
| Location | 12541 Highway 27, Summerville, Georgia |
|---|
| No. of Dialysis Stations | 16 |
|---|
| Medicare ID | 112795 |
|---|
| Managed By | Independent |
|---|
| Ownership Type | Profit |
|---|
| Late Shifts | No |
|---|
NPI Associated with this Dialysis Facility:
Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Biomedical Applications Of Georgia, Inc
from NPPES records by matching pattern on the basis of name, address, phone number etc.
Please use this information accordingly.
| NPI Number | 1053823864 |
| Organization Name | Fresenius Kidney Care Chattooga County |
| Doing Business As | Bio-medical Applications Of Georgia, Inc. |
| Address | 12541 Highway 27 Summerville, Georgia, 30747 |
| Phone Number | (706) 857-4050 |
| NPI Number | 1861680118 |
| Organization Name | Harbin Clinic Summerville Dialysis Center |
| Doing Business As | Harbin Clinic, Llc |
| Address | 12541 Highway 27 Summerville, Georgia, 30747 |
| Phone Number | (706) 238-8088 |
Patient Distribution
Anemia Management
| Dialysis patients with Hemoglobin data | 25 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 4 |
Dialysis Adequacy
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
- Hemodialysis
| Adult patients getting regular hemodialysis at the center | 49 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 379 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center | |
Mineral and Bone Disorder
An important goal of dialysis is to maintain normal levels of various minerals
in the body, such as calcium. This shows the percentage of patients
treated at Biomedical Applications Of Georgia, Inc with elevated calcium levels.
| Patients with hypercalcemia | 52 |
| Hypercalcemia patient months | 388 |
| Patients with Serumphosphor | 55 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
Vascular Access
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it
allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access.
Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 39 |
| Patient months included in arterial venous fistula and catheter summaries | 279 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 53 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
Hospitalization Rate
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the
hospital more often (worse than expected), less often (better than expected), or about the same (as expected),
compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 52 |
| Hospitalization Rate in facility | 210.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 353.7 |
| Hospitalization Rate: Lower Confidence Limit | 129.6 |
Readmission Rate
The rate of readmission show you whether patients who were being treated regularly at Biomedical Applications Of Georgia, Inc
were readmitted more often (worse than expected), less often (better than expected), or
about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 35.6 |
| Readmission Rate: Lower Confidence Limit | 16 |
Infection Rate
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to
enter the body and cause infection. This information shows how often patients at Biomedical Applications Of Georgia, Inc get infections in their blood each year
compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.4 (As Expected) |
| SIR: Upper Confidence Limit | 3.81 |
| SIR: Lower Confidence Limit | .36 |
Transfusion Summary
Patients with anemia require blood transfusions if their anemia is not managed well by their
dialysis center. This information shows whether Biomedical Applications Of Georgia, Inc's rate of transfusions is better than expected,
as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 42 |
| Transfusion Rate in facility | 20.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 97.6 |
| Transfusion Rate: Lower Confidence Limit | 5 |
Survival Summary
The rate of mortality show you whether patients who were being treated regularly at Biomedical Applications Of Georgia, Inc lived longer than
expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared
to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 235 |
| Mortality Rate in facility | 19.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26 |
| Mortality Rate: Lower Confidence Limit | 14.1 |